局部晚期前列腺癌根治性前列腺切除术前新辅助化疗内分泌治疗对比内分泌治疗的前瞻性随机试验
本随机试验纳入141例局部晚期高危前列腺癌患者,按2:1随机分为多西他赛为基础的新辅助化疗内分泌治疗(NCHT)组和单纯新辅助内分泌治疗(NHT)组,主要终点为3年生化进展无生存(bPFS)。结果显示NCHT组3年bPFS显著优于NHT组(29% vs 9.5%,P = .002),但病理降期和微小残留病灶率无显著差异。
要点
- NCHT组3年bPFS为29%,NHT组为9.5%(P = .002)
- 中位随访53个月,NCHT组中位bPFS 17个月 vs NHT组14个月
- 两组病理降期和微小残留病灶率无显著差异
核心结论
- 在高危局部晚期前列腺癌中,根治性前列腺切除术前多西他赛为基础的新辅助化疗内分泌治疗较单纯新辅助内分泌治疗取得显著bPFS获益。
- 作者认为需要更大样本量和更长随访时间进一步研究。
研究设计与样本
- 前瞻性随机试验,纳入141例局部晚期高危前列腺癌患者,按2:1随机分配至NCHT组和NHT组。
- NCHT组方案为多西他赛75 mg/m2体表面积每3周一次联合雄激素剥夺治疗共6周期;NHT组为雄激素剥夺治疗24周。
- 主要终点为3年bPFS,次要终点包括病理缓解(病理降期和微小残留病灶率)。
主要发现
- NCHT组3年bPFS为29%,NHT组为9.5%,差异有统计学意义(P = .002)。
- 中位随访53个月,NCHT组中位bPFS时间为17个月,NHT组为14个月,NCHT组显著更长。
- 两组病理降期率和微小残留病灶率均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要更大样本量和更长随访时间进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Benefits of docetaxel-based neoadjuvant chemohormonal therapy (NCHT) before radical prostatectomy (RP) remain largely unknown. We explored whether docetaxel-based NCHT would bring pathological benefits and improve biochemical progression-free survival (bPFS) over neoadjuvant hormonal therapy (NHT) in locally advanced prostate cancer. MATERIALS AND METHODS: A randomized trial was designed recruiting 141 locally advanced, high-risk prostate cancer patients who were randomly assigned at the ratio of 2:1 to the NCHT group (75 mg/m2 body surface area every 3 weeks plus androgen deprivation therapy for 6 cycles) and the NHT group (androgen deprivation therapy for 24 weeks). The primary end point was 3-year bPFS. Secondary end points were pathological response including pathological downstaging and minimal residual disease rates. RESULTS: The NCHT group showed significant benefits in 3-year bPFS compared to the NHT group (29% vs 9.5%, P = .002). At a median follow-up of 53 months, the NCHT group achieved a significantly longer median bPFS time than the NHT group (17 months vs 14 months). No significant differences were found between the 2 groups in pathological downstaging and minimal residual disease rates. CONCLUSIONS: NCHT plus RP achieved significant bPFS benefits when compared with NHT plus RP in high-risk, locally advanced prostate cancer. A larger cohort with longer follow-up duration is essential in further investigation.
引用
- Qian H, Chi C, Tricard T, et al. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy. J Urol. 2024. PMID: 38591703. doi:10.1097/JU.0000000000003876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。